Lonoctocog Alfa News
Lonoctocog Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Lonoctocog Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Afstyla can be used for all age groups.
- Evidence level: L5
- Predicted indications (20):
- pseudo-von Willebrand disease (99.8%)
- primary release disorder of platelets (99.8%)
- Glanzmann thrombasthenia (99.8%)
- Scott syndrome (99.4%)
- symptomatic form of hemophilia in female carriers (99.3%)
- hemophilia (99.3%)
- acquired coagulation factor deficiency (98.8%)
- bleeding diathesis due to a collagen receptor defect (98.7%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (98.6%)
- esophageal varices without bleeding (98.4%)
- esophageal varices with bleeding (98.4%)
- thrombotic thrombocytopenic purpura (98.1%)
- hemophilia A with vascular abnormality (97.7%)
- varicose disease (97.6%)
- factor XI deficiency (97.1%)
- familial apolipoprotein C-II deficiency (96.5%)
- fetal and neonatal alloimmune thrombocytopenia (96.5%)
- primary immunodeficiency syndrome due to p14 deficiency (96.1%)
- flood factor deficiency (96.0%)
- hemorrhagic disorder due to a platelet anomaly (95.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.